Our findings are partially supported by previous studies (Fig. 6), however, these studies included some patients with IDH-mutant gliomas, which usually have a better prognosis, and are no longer classified as glioblastoma [15, 16]. This evidence concerns the gene IDH2 and central nervous system cancer.